Research peptides · For laboratory and scientific research in vitro · Not medications · Not approved for consumption · Adults only (18+)
SLU-PP-332 — selective ERRα/β/γ agonist for mitochondrial biogenesis
In short
Mimics the effects of a workout — increases physical endurance and helps the body burn fat without extra exercise.
Overview
SLU-PP-332 is a triple ERR agonist — the first small molecule to activate all three estrogen-related receptor isoforms with similar potency. ERRs are nuclear receptors that regulate oxidative metabolism, mitochondrial function, and fiber-type composition in skeletal and cardiac muscle. The compound is investigated as an 'exercise pill' candidate — a pharmacological mimic of the cellular adaptations driven by endurance training.
Pan-agonism at ERRα, ERRβ, and ERRγ upregulates PGC-1α coactivation targets — driving mitochondrial biogenesis, fatty-acid β-oxidation enzymes, and a shift toward slow-twitch oxidative muscle phenotype. The transcriptional program overlaps substantially with that induced by endurance exercise.
Molecular information
Ограничени данни за безопасност — само предклинични. Не е установен сигнал от човешка фармаковигиланция. Изследователите трябва да третират съединението с пълна предпазливост за изследователски съединения, включително стандартни критерии за изключване за неизследвани нуклеарни рецепторни модулатори (бременност, хормонално-чувствителни състояния).
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Information about SLU-PP-332 is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadNo comments yet. Be the first.
Comments are reviewed before publishing.
